#Cambridge #United Kingdom #AstraZeneca #IgniteData #Archer

IgniteData's Archer Tool Revolutionizes Clinical Trials

In a groundbreaking development for clinical research, IgniteData has partnered with AstraZeneca and Cambridge University Hospitals NHS Foundation Trust (CUH) to introduce its innovative data integration platform called Archer. This tool is designed to transform the clinical trial process through superior automation and digital technologies, thereby streamlining data handling in studies.

The Importance of Automation in Clinical Research

Clinical trials often involve substantial amounts of data that need to be collected, recorded, and processed. Traditionally, this data entry is time-consuming and prone to errors, which can hinder research efficiency and outcomes. IgniteData's Archer aims to address these issues by providing a robust solution that automates the transfer of data from Electronic Health Records (EHRs) to Electronic Data Capture (EDC) systems.

According to Richard Yeatman, COO of IgniteData, “Our partnership with Cambridge University Hospitals and AstraZeneca is significant in paving the way for advanced methodologies in clinical research. With Archer, the data integration process becomes seamless, ensuring secure and efficient transfer, which is pivotal for achieving successful patient outcomes.”

Enhanced Features of Archer

The Archer tool stands out due to its system-agnostic design, allowing it to integrate with leading EHRs and EDCs without compatibility issues. It efficiently maps numerous study variables, transferring hundreds of data points for each patient while safeguarding data privacy and integrity. This means that researchers can allocate more time to actual clinical research instead of being bogged down by administrative tasks like data entry.

In addition, the collaboration with AstraZeneca has been pivotal since its inception in 2021, where AstraZeneca played a crucial role in developing the Archer platform. After successful pilot studies at notable institutions like University College London Hospitals (UCLH) and Memorial Sloan Kettering Cancer Center (MSK), the Archer tool is set to make its full debut in this crucial Phase 3 clinical trial at the Cambridge site.

Commitment to Ethical Research Practices

Patient involvement and consent have been paramount throughout the process. All participants in the study have previously granted their permission for the use of their clinical data. Dr. Wai Keong Wong, Clinical Director of Digital Transformation at CUH, expressed the transformative potential of Archer, stating, “The integration of this tool into our systems represents a monumental advancement in our approach to clinical trials, promoting both efficiency and the integrity of our data.”

Future Expansion and Impact

The launch of Archer at Cambridge signifies not just an isolated success but a larger vision for the digitization of clinical trials across other NHS and European hospital systems. The insights gained from this live implementation will help tailor subsequent deployments across diverse healthcare institutions, ensuring a wider-reaching impact.

IgniteData envisions Archer as a stepping stone towards a global initiative, ultimately aiming to revolutionize how clinical trials are conducted and accelerating the pace at which life-saving medical treatments reach patients.

For further details about the Archer platform and its significant role in enhancing clinical trials, interested parties can visit IgniteData’s official website. As the future of clinical research unfolds, tools like Archer exemplify the potential that digital innovation holds in transforming patient care and research efficiency.

About IgniteData

IgniteData is a pioneering company at the forefront of reshaping clinical trials with its advanced digital health platform, Archer. By fostering interoperability between EHR systems and crucial research applications like EDC, IgniteData is playing a vital role in the evolution of clinical research methodologies.